Diethylstilbestrol dosage form and methods of treatment using thereof
Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, particularly diethylstilbestrol and pharmaceutically acceptable salts thereof to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract.
1. A method for treating prostate or breast cancer in a patient comprising
administering the oral unit dosage form as a water soluble matrix to the oral mucosal membranes of the mouth of a patient, which matrix contains, dispersed therein, a pharmaceutical agent selected from the group consisting of diethylstilbestrol and pharmaceutically acceptable salts of diethylstilbestrol, said pharmaceutical agent being present in said matrix in an amount effective for treating said prostate or breast cancer, said matrix composed of a one or more sucrose fatty acid esters having an HLB of about 8 to 16, wherein the matrix is a film whereby the pharmaceutical agent is absorbed through the mucosal membrane providing high blood levels of diethylstilbestrol and low levels of fibrinogen.
2. The method of claim 1 , further comprising a polymeric mixture of polyvinyl pyrrolidone and a polymeric alginate.
3. The method of claim 2 , wherein the ratio of polyvinyl pyrrolidone to polymeric alginate in the polymeric mixture is from about 5:1 to about 1:3.
4. The method of claim 2 , wherein the polymeric mixture contains, from about 5% to about 95% by weight of polyvinyl pyrrolidone and from about 5% to about 95% by weight of an polymeric alginate, both of said weights being based on the weight of said polymeric mixture.
5. The method of claim 1 , wherein the diethylstilbestrol and pharmaceutically acceptable salts of diethylstilbestrol is present in an amount of about 0.1 to about 5 mg.
6. The method of claim 1 , wherein said matrix is placed under the tongue of said patient.
7. The method of claim 1 , wherein said matrix is inserted on the buccal tissue of the mouth of the patient.
8. The method of claim 1 , wherein the sucrose fatty acid ester has a monomer content of from about 20 percent to about 80 percent.
9. The method of claim 1 , wherein the sucrose fatty acid esters are selected from the group consisting of sucrose stearate, sucrose palmitate, sucrose laurate, sucrose behenate, sucrose oleate and sucrose erucate.
10. The method of claim 1 , wherein said absorption enhancer is present in an amount of from about 1% to about 20% based upon the weight of the film.
11. The method of claim 1 , further comprising a nonionic surfactant wherein the combined nonionic surfactant and sucrose fatty acid ester have a combined HLB of about 8 to about 17.
12. The method of claim 1 , further comprising a secondary absorption enhancer selected from the group consisting of glycerol, tween, span, ginger oil, cineole and terpenes.
13. The method of claim 1 , further comprising pullulan as a film forming agent.
14. The method of claim 1 , wherein the active agent is released over a period of time from about 0.25 minutes to about 15 minutes.
15. The method of claim 1 , wherein the active agent is released over a period of time from about 0.5 minutes to about 10 minutes.
16. The pharmaceutical composition of claim 1 , further comprising a film forming agent selected from pullulan or a polymeric mixture of polyvinyl pyrrolidone and a polymeric alginate.
17. The pharmaceutical composition of claim 1 , further comprising a film forming agent selected from pullulan.